{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCAA&page=27",
    "query": {
      "intervention": "BCAA",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 15661,
    "total_pages": 1567,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCAA&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCAA&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T17:50:44.055Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04106362",
      "title": "Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "KRAS Protein Variant",
        "Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2020-01-14",
      "completion_date": "2023-05-23",
      "has_results": false,
      "last_update_posted_date": "2023-06-01",
      "last_synced_at": "2026-10-30T17:50:44.055Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04106362"
    },
    {
      "nct_id": "NCT07257042",
      "title": "Oothpaste Containing 8% Arginine Compared to Colgate Cavity Protection Toothpaste in Reducing Dentinal Hypersensitivity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "Toothpaste containing 8% Arginine",
          "type": "DRUG"
        },
        {
          "name": "Colgate Cavity Protection Toothpaste",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Colgate Palmolive",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 80,
      "start_date": "2025-07-14",
      "completion_date": "2025-11-04",
      "has_results": false,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-10-30T17:50:44.055Z",
      "location_count": 1,
      "location_summary": "Loma Linda, California",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07257042"
    },
    {
      "nct_id": "NCT01502670",
      "title": "Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "18F-FACBC Radiotracer",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2009-05",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-10-30T17:50:44.055Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01502670"
    },
    {
      "nct_id": "NCT01577173",
      "title": "A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "MEHD7945A",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2012-07",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-30T17:50:44.055Z",
      "location_count": 14,
      "location_summary": "Stanford, California • Aurora, Colorado • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Paducah",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01577173"
    },
    {
      "nct_id": "NCT00807573",
      "title": "Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2008-12",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2015-12-30",
      "last_synced_at": "2026-10-30T17:50:44.055Z",
      "location_count": 5,
      "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rockville Centre",
          "state": "New York"
        },
        {
          "city": "Sleepy Hollow",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00807573"
    },
    {
      "nct_id": "NCT00863369",
      "title": "Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2005-06-29",
      "completion_date": "2023-06-20",
      "has_results": true,
      "last_update_posted_date": "2024-03-20",
      "last_synced_at": "2026-10-30T17:50:44.055Z",
      "location_count": 2,
      "location_summary": "Duarte, California • South Pasadena, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00863369"
    },
    {
      "nct_id": "NCT03101969",
      "title": "Human Outreach to Improve Adherence With Scheduled Pain Clinic Appointments",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Patient Compliance"
      ],
      "interventions": [
        {
          "name": "Call",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1022,
      "start_date": "2014-08",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2017-04-05",
      "last_synced_at": "2026-10-30T17:50:44.055Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03101969"
    },
    {
      "nct_id": "NCT02633683",
      "title": "An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "RLS"
      ],
      "interventions": [
        {
          "name": "HORIZANT 600 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "XenoPort, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "13 Years to 17 Years"
      },
      "enrollment_count": 144,
      "start_date": "2016-01",
      "completion_date": "2024-07",
      "has_results": false,
      "last_update_posted_date": "2021-06-09",
      "last_synced_at": "2026-10-30T17:50:44.055Z",
      "location_count": 11,
      "location_summary": "Redwood City, California • San Diego, California • Gulf Breeze, Florida + 8 more",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02633683"
    },
    {
      "nct_id": "NCT00869323",
      "title": "Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoproliferative Disorder"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2009-03",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-10-30T17:50:44.055Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • St Louis, Missouri",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00869323"
    },
    {
      "nct_id": "NCT05023980",
      "title": "A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pirtobrutinib",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Loxo Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 282,
      "start_date": "2021-09-23",
      "completion_date": "2027-10",
      "has_results": true,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-30T17:50:44.055Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Whittier, California • Coral Springs, Florida + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Brick",
          "state": "New Jersey"
        },
        {
          "city": "Westbury",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05023980"
    }
  ]
}